Ylva Ginsberg, M.D., Ph.D., is currently working as chief consultant psychiatrist at the Stockholm county council, Sweden, and has spent more than fifteen years assessing and treating adults with neurodevelopmental disorders, primarily ADHD, within specialized units of the Swedish psychiatric healthcare.
As a member of the European Network Adult ADHD, she was involved in the Swedish translation of the Diagnostic Interview for ADHD in adults (DIVA), and she co-authored the frequently cited European consensus statement on diagnosis and treatment of adult ADHD (Kooij et al., 2010),
and she is also an co-author of the ongoing update of the consensus statement. Other international collaborations include the ECNP Network ADHD across the lifespan, and the IMpACT group.
Dr. Ginsberg has also served as principal investigator and Swedish coordinator of several international multicentre methylphenidate trials conducted in adults with ADHD.
Dr. Ginsberg earned her Ph.D. degree in 2012 at Karolinska Institutet, Stockholm, Sweden,
with a thesis about assessment and pharmacological treatment of ADHD in adult prison inmates.
She and her collaborators were the first to evaluate methylphenidate as treatment for adult male long-term prison inmates with ADHD and coexistent disorders in an investigator-initiated 52-week randomised controlled trial. Completers of the trial were then followed-up for three years in a naturalistic observational study. Following the successful results of her research, the Swedish Prison and Probation Services in Sweden have initiated screening, assessment and treatment of ADHD on a regular basis.
As an affiliated post-doctoral researcher at Karolinska Institutet, she is conducting register-based studies exploring early risk factors for developing ADHD, and long-term effects of ADHD medication. Furthermore, she is involved in studies of the overlap between eating disorders and ADHD in a large clinical cohort, and also in trials evaluating internet-delivered CBT as well as computer assisted cognitive training in adults with ADHD. Moreover, she is taking part in a national study of WHODAS 2.0, validating the instrument in a Swedish clinical cohort of adults with ADHD and coexistent disorders.
Dr. Ginsberg is an appreciated reviewer for several scientific journals, and also for governmental reports and guidelines. She served as an independent expert and co-author of the recently updated Swedish treatment guidelines for ADHD in children and adults (the Swedish Medical Products Agency, 2016).
Dr. Ginsberg regularly gives lectures on ADHD and autism spectrum disorders for medical students and residents in psychiatry, and she has co-authored a textbook on these topics.
She is also a frequent speaker at Swedish and international medical meetings.
To contact GME, email us at [email protected]